key: cord-0774660-ymtfgebz
authors: Cyprian, Farhan; Sohail, Muhammad Umar; Abdelhafez, Ibrahim; Salman, Salma; Attique, Zakria; Kamareddine, Layla; Al-Asmakh, Maha
title: SARS-CoV-2-Immune-Microbiome Interaction: Lessons from Respiratory Viral Infections
date: 2021-02-18
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.071
sha: 9acc8a6dda4dfc51c167e641771c3cf4b0b95c0f
doc_id: 774660
cord_uid: ymtfgebz

By the beginning of 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly evolved into an emergent worldwide pandemic, an outbreak whose unprecedented consequences highlighted the existing flaws within the global public healthcare systems. While the coronavirus disease 2019 (COVID-19) is bestowed with a broad spectrum of clinical manifestation involving vital organs, the respiratory system transpires as the main route of entry of SARS-CoV-2, with the lungs being its primary target. Of those infected, up to 20% require hospitalization on account of severity, while the majority of patients are either asymptomatic or exhibit mild symptoms. Exacerbation in disease severity and complications of COVID-19 infection have been allied with multiple comorbidities including hypertension, diabetes mellitus, cardiovascular disorders, cancer, and chronic lung disease. Interestingly, a recent body of evidence have foregrounded the pulmonary and gut microbiome as potential modulators in altering the course of COVID-19, plausibly via the microbiome-immune system axis. While relative concordance between microbes and immunity is still not fully elucidated in a COVID-19 disease context, we present here an overview of our current understanding of this COVID-19-microbiome-immune cross talk and discuss the potential contributions of microbiome-related immunity to SARS-CoV-2 pathogenesis and COVID-19 disease progression.

shown to be similar to that of community-acquired pneumonia patients, with either pathogenic dominance or elevation in the levels of oral and upper respiratory commensal bacteria (Shen et al., 2020) . Interestingly, the substantial differences in COVID-19associated mortality has been recorded between developed and developing countries (Kumar and Chander, 2020) . The authors found that COVID-19-associated mortality was positively correlated with hygiene, water quality, and overall health care efficiency. Therefore, it is suggested that high microbial exposure due to lack of sanitation could possibly induce interferons, which might have a protective effect against COVID-19 (Kumar and Chander, 2020) . Individuals from low-income countries with reduced COVID-19 related mortality are thought to have more diverse microbiota as the microbiota regularly provides tonic immune signals, thereby influencing host susceptibility to infections (Pang and Iwasaki, 2012) .

Microbiome-induced immune-priming, for example, can activate type I interferon production, providing protection against COVID-19 (Monroe et al., 2010 , Taefehshokr et al., 2020 .

Antibiotics are widely used as a broad-spectrum therapeutic approach to prevent secondary infections. For instance, 58-71% of the COVID-19 patients in China received antibiotics, and 2-36% of patients suffered gastric complications, including diarrhea (Guan et al., 2020) . It is well known that antibiotics alter the normal gastrointestinal tract (GIT) flora. In this context, observed that COVID-19 patients who did not receive antibiotics had higher number of opportunistic pathogens, known to cause bacteremia (Dakshinamoorthy et al., 2019, Elsayed and Zhang, 2004) . However, empirical antibiotic It is well known that persistent exposure to bacterial toxins, as we age, results in chronic low-grade inflammation, recurrent infections, excessive medication, and hospitalizations (Nagpal et al., 2018) . Moreover, owing to the paralleled evolution between our microbiome and immunity, the diversity of the gut microbiome tends to fluctuate with age (Nagpal et al., 2018) , with a significant reported decline in the numbers of lactobacilli and bifidobacteria, and an increase in Clostridium perfringens, Clostridium difficile and enterobacteria, as we grow older (Gavini et al., 2001 , Odamaki et al., 2016 . Other studies have shown a similar age-related shift in the gut microbiome composition and diversity in respiratory tract microbiome, particularly in Rothia and Streptococcus overgrowth (de Steenhuijsen Piters et al., 2016 , Stearns et al., 2015 . Although it remains unclear whether microbiome dysbiosis is a cause or effect of aging and senescence-related inflammatory disorders, it has been hypothesized that a healthy microbiome is essential for healthy aging, and restoring microbiome homeostasis can promote human longevity.

As in aging, comorbid conditions such as hypertension and cancer have been associated with microbial dysbiosis in the gut and respiratory tract (Hosgood III et al., 2019 , Michalovich et al., 2019 , Zhang Chenting et al., 2020 . Emerging body of evidence highlights the changes in the gut microbiome of obese and diabetic patients and addresses their role in disease pathogenesis. Hyperglycemia and hyperlipidemia are likely to create suitable environments, that may attract some bacteria to flourish (Sohail et al., 2017) . Furthermore, hypoxic niches that impact bacterial survival may also be generated due to airway closure that often accompanies obesity (Salome et al., 2010) . Although much is yet to be elucidated here, it is very conceivable that lung microbial communities are also altered by DM and obesity. Zhang et al. reported that patients with hypertension exhibit an upregulation in bacterial invasion-related genes and bacterial toxins in the respiratory tract, along with an overgrowth of several opportunistic pathogens, namely Lautropia, Streptococcus, and J o u r n a l P r e -p r o o f Ralstonia (Zhang Chenting et al., 2020) . Similarly, cancer-associated lung microbiome is also distinct, represented by low diversity and species richness and an overgrowth of Streptococcus in comparison to control group (Liu et al., 2018) . This suggests a direct connection between lung cancer and microbiome, where microbial agents and/or products may promote carcinogenesis that eventually favors immunosuppression and provides environment suitable for lung infections.

For a better understanding of the wide spectrum of clinical manifestations in COVID-19 patients ranging from minor upper respiratory tract infection (URTI) to sepsis, researchers studied a plethora of data and identified several risk factors including hypertension, DM, cancer and ischemic heart diseases associated with adverse outcomes. (Robilotti et al., 2020 , Zhou Fei et al., 2020 . Interestingly, microbiome dysbiosis was also classified among the significant risk factor contributing to these chronic diseases (Rook and Immunology, 2010) as both microbial dysbiosis and pro-inflammation are known to initiate and accumulate epigenetic changes that culminate in chronic inflammatory responses in DM, obesity, and cancer, increasing morbidity due to sepsis (Serino, 2018) . These observations are similar to the immune response observed in sepsis where activation of the innate immune system via pattern recognition receptors (PRR) like TLR-4 recognizing pathogen associated molecular patters (PAMPs) like lipopolysaccharide (LPS) leads to overproduction of pro-inflammatory cytokines.

Patients

The upper respiratory tract (URT) is in direct exposure to the outside atmosphere and also closely correlates with the skin microbiome. Therefore, the URT provides a diverse J o u r n a l P r e -p r o o f landscape of micro-niches for microbial attachment. For instance, anterior naris harbors commensals and opportunistic pathogens including Staphylococcus aureus, Anaerococcus, Dolosigranulum pigrum, Corynebacterium spp., and Moraxella spp., which are distinct from the mucosal communities of the nasal cavity and the pharynx (Wos-Oxley et al., 2010) .

Examples of commensal microbiota that normally colonizes the URT include Staphylococcus, Streptococcus, Prevotella, and Veillonella. These presumably prevent overgrowth and dissemination of potential pathogens towards the lower respiratory tract (LRT), thereby acting as gatekeepers of the lungs (Kumpitsch et al., 2019) . Physiological and microbial gradients along the URT indicate that the highest bacterial load is in the oropharynx and the lowest is in the naris. Interestingly, several studies reported changes in URT microbiome during viral infections including coronavirus influenza, rhinovirus, and respiratory syncytial virus infections, rendering the host more susceptibility to infection.

Acute viral infections, for example, are associated with significant changes in the nasopharyngeal core microbiome and are characterized by a decrease in alpha-diversity and an abundance of beneficial microbes, specifically anaerobes and Prevotella (Edouard et al., 2018) . Moreover, respiratory pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Corynebacterium propinquum, were found to be enriched in patients with viral infections. Interestingly, the type of viral infection did not seem to influence the microbial profile. (Bouquet et al., 2020 , Edouard et al., 2018 . Similarly, Yi et al. (Yi et al., 2014) did not find any relationship between oropharyngeal microbiota and the type of viral agent when studying different viral respiratory illnesses. Instead, microbiome clustering was found to be related to subjects' age, with over-representation of Moraxella nonliquefaciens in younger patients (Yi et al., 2014) .

Previous studies have shown that viral infections enhance bacterial adherence to the epithelium and increase pathogenic bacterial colonization. The microbial composition of the J o u r n a l P r e -p r o o f URT, for example, is altered by viral infections, promoting the translocation of pathogens to the lungs and thus predisposing infected hosts to secondary infections (Dube et al., 2016) . Safaeyan et al. (Safaeyan et al., 2015) demonstrated that symptomatic patients infected with influenza A have higher colonization rates of Staphylococcus aureus, S. pneumoniae and H.

influenzae. In contrast, asymptomatic influenza A virus carriers exhibit a microbiome strictly comparable to healthy subjects, suggesting a critical role of the nasopharyngeal microbiome in the clinical presentation of viral infections (Yi et al., 2014) . It is well known that the commensal microbiotas are essential for development of the mucosal immune system (Neish, 2014 ). The mucosal microbiome was shown to influence the immune system locally across multiple pathways by either enhancing or minimizing the viral infection via bacterial ligands that occupy viral receptors (Bosch et al., 2013) . Particularly, the genus Prevotella;

constituting 50% of the core microbiome of healthy subjects (de Steenhuijsen Piters et al., 2016) , has many member strains (Prevotella melaninogenica, Prevotella nanceiensis, and Prevotella salivae) that show no pro-inflammatory effects on human dendritic cells (DCs) and play a protective role in reducing secretions of pro-inflammatory cytokines induced by pathogens, such as H. influenzae (Larsen et al., 2012) . Prevotella has also been shown to decrease significantly in influenza and sinusitis patients, while Corynebacterium propinquum has been associated with susceptibility to viral infections (Edouard et al., 2018 , Leung et al., 2013 . Therefore, preventive or therapeutic interventions may be guided to preserve or restore a healthy microbiome of the nasopharynx in order to regulate a healthy innate and adaptive immune responses against viral infections.

Since the dawn of the germ theory, it was widely assumed that healthy lungs are germfree, a thought that initially excluded studying the lungs in the National Institutes of Health Human Microbiome Project (Proctor, 2011) . Recently, however; high throughput sequencing J o u r n a l P r e -p r o o f techniques have revealed that healthy lungs are indeed populated by diverse bacterial communities although relatively fewer in number as compared to those in GIT (Sohail et al., 2015) . Thus, studying the lung microbiome in health and pathological conditions is emerging as one approach to re-visit respiratory diseases, particularly those involving an infectious aspect, including pneumonia, cystic fibrosis, asthma, emphysema, and chronic obstructive pulmonary disease (COPD). Interestingly, similar to that of the intestine, the lung mucosal immunity has been also shown to be engaged in maintaining an equilibrium state of tolerance and immune activation against pathogens (Lloyd and Marsland, 2017) .

Although only few studies were so far directed towards unravelling the human lung microbiome in a healthy status, most gathered evidence indicate the existence of a complex and dynamic microbial community predominantly composed of phylum Firmicutes, Proteobacteria, and Bacteroidetes (Dickson et al., 2015) . At the genus level, Prevotella, Veillonella, Streptococcus, Methylobacterium, Neisseria, Pseudomonas, and Fusobacteria predominate, and to a lesser extent possible pathogens, including Leptotrichia and Haemophilus, were detected (Dickson et al., 2015, Moffatt and Cookson, 2017) . It is worth noting here that lung sampling for microbiome analysis is considered invasive and could therefore be technically problematic. Alternatively, sputum collection is considered instead for diagnosis of lower respiratory tract (LRT) infections. Contamination is another challenging aspect here. The bronchoscope passage through the oral or nasal route entails the possibility of sample contamination. Moreover, oropharyngeal contamination renders a sputum specimen not fit for microbiome studies. As such, and taken with the low biomass availability during sampling, the validity of lung microbiome reports have been challenged These studies suggest that microbial communities in the lung are altered in viral infections, improving host immunity and disease severity (Eskind et al., 2020 , Hanada et al., 2018 , Ichinohe et al., 2011 , Molyneaux et al., 2013 . For instance, the lung microbiome analysis of HIV-positive patients showed a T-helper cell response and mortality rate correlated with clustering pattern of a distinct microbiome (Shenoy et al., 2017) . Moreover, the respiratory microbiome of HIV-patients with advanced disease had decreased alpha diversity and increased beta diversity compared to healthy individuals (Twigg III et al., 2016) . Along those lines, Eskind et al. reported that respiratory microbiome diversity is compromised by acute viral infections with a decline in alpha diversity accompanied by a high prevalence of bacterial pathogens (Eskind et al., 2020) . In contrast, Yildiz et al. observed no changes in alpha and beta diversity in the lung microbiome of influenza-infected mice (Yildiz et al., 2018) . Another study, investigating influenza infections, found that commensals are essential for generating specific CD4 and CD8 T cells and antibody responses. Particularly, the existing microbiome provided signals for pro-IL-1β and pro-IL-18 cytokines and inflammasome activation leading to DCs migration and T-cell priming (Ichinohe et al., 2011) . Moreover, influenza infection altered the microbiome composition and promoted the release of pro-inflammatory cytokines, C reactive protein, and increased mucus production in the respiratory tract. Similarly, rhinovirus exacerbation in COPD patients increased bacterial pathogen load, especially Haemophilus influenzae, correlating that with an increase in inflammatory markers (Molyneaux et al., 2013) .

Acute respiratory distress syndrome (ARDS) is a serious complication that often occurs in severe influenza, MERS-CoV and SARS-CoV infections. Irrespective of the infection source, the lung microbiome of ARDS patients was found enriched with gut bacteria and correlated with alveolar and systemic inflammation intensity (Dickson et al., 2016) . Bacterial J o u r n a l P r e -p r o o f toxins, such as lipopolysaccharides and flagellin, cause inflammation in patients with ARDS resulting in pneumonia by mainly engaging PRRs such as TLRs 4 and 5 respectively. The accumulation of inflammatory cells and cytokines and excessive mucus production during ARDS leads to obstruction of the airway by impeding mucociliary clearance, providing an anaerobic environment for putative bacteria's growth and secondary infections. Overaccumulation of gut pathogens, including Enterobacteriaceae and Bacteroides, in the lungs of critically ill ARDS patients may lead to sepsis and respiratory failure (Dickson et al., 2020 , Dickson et al., 2016 . Dickson et al. observed that severe cases of ARDS patients had higher bacterial burden and richness but lower bacterial diversity (Dickson et al., 2020) . Furthermore, microbial dysbiosis was shown to be significantly associated with TNF-α, a principal mediator of inflammation in ARDS (Dickson et al., 2016) .

reported that the microbiome of lung tissue in 20 deceased COVID-19 patients was dominated by Acinetobacter, a common pathogen in lung infections that may cause pneumonia. Furthermore, opportunistic pathogens such as Cryptococcus, Cladosporium, Issatchenkia, Alternaria, Aspergillus, and Candida were also dominant in the lung mycobiome of deceased patients. Some of these pathogens can be lethal, particularly

Cryptococcus infection which is linked to a high morbidity and mortality rate (Fan Jun et al., 2020 

The gut microbiome performs several important functions including metabolizing nutrients, resisting pathogenic colonization, maintaining the bowel barrier, and educating the immune system (Al-Asmakh and Hedin, 2015, Althani et al., 2016 , Sohail et al., 2019 .

Additionally, it has been recently reported that changes in the gut microbiome composition has various systemic effects, particularly those exhibited via the gut-brain neuroendocrine and the gut-lung inflammatory axes (El Aidy et al., 2015) . Germ-free mice were shown to substantially have underdeveloped gut-associated lymphoid tissues, reduced Peyer patches and mesenteric lymph nodes, as well as compromised production of antibodies against pathogens. Akin to that, recent studies investigated the effects of gut microbiome on respiratory tract immunity (Anand and Mande, 2018 , Deriu et al., 2016 , Groves et al., 2018 , Marsland et al., 2015 , Zhang Dapeng et al., 2020 , and reported a bidirectional cross talk ( Figure 3 ) between gut microbiome composition and respiratory tract infections. Mice maintained on a fibrous diet, for example, showed an increased survival rate and resisted lung damage, a phenotype attributed to the increased production of short-chain fatty acids (SCFAs) during influenza infection (Trompette et al., 2018) . Interestingly, SCFAs reduced inflammation and conferred protection against influenza by promoting Ly6c-patrolling monocytes, CD8+ T cell effector functions, and activating macrophages (Trompette et al., 2018) . In addition, Smith et al. (2013) demonstrate the importance of SCFAs and microbial metabolites in promoting the immune suppressive regulatory T cell (Treg) population in the gut to maintain tolerance . Likewise, a higher population of butyrate-producing bacteria in the fecal microbiota is associated with increased resistance to respiratory viral infection (Haak et al., 2018) . Moreover, a study by Sencio et al. (2020) showed that gut microbiome dysbiosis during influenza infection promotes respiratory pneumococcal superinfection through altered SCFAs production. They also showed that acetate supplementation decreased susceptibility to secondary bacterial infection by enhancing alveolar macrophage activity.

More recently, Gu et al (Gu et al., 2020) compared the gut microbiome of influenza virus patients with healthy controls and COVID-19 patients. The authors observed that patients with influenza infection displayed lower diversity and overall different microbial composition than healthy controls and COVID-19 patients. Particularly, butyrate-producing J o u r n a l P r e -p r o o f bacteria including, Ruminocacceae and Lachnospiraceae families, were decreased significantly in influenza patients. In a study conducted in germ-free mice, Abt et al. revealed the importance of commensal bacteria in calibrating the threshold activation of innate antiviral immunity (Abt et al., 2012) . Within this frame of reference, respiratory influenza infection was shown to induce intestinal inflammation, promote immune dysregulation, and alters the gut microbiome by particularly increasing Enterobacteriaceae and decreasing

Lactococci and Lactobacilli populations in murine models (Wang et al., 2014) .

Interestingly, lung-derived CD4 + T cells in the gut were shown to be responsible for these changes, via producing IFN-γ that mediate microbiome associated shifts and promote immune mediated injury in the intestine. Similarly, gut microbiome dysbiosis was shown to be associated with respiratory syncytial virus (RSV) disease severity in infants. Patients with severe RSV disease have lower alpha diversity in the gut microbiota, characterized by enrichment of Actinomyces, Clostridiales, Lactobacillaceae, and Odoribacteraceae (Cormier et al., 2020) . These data collectively suggest a cross talk between respiratory viral infections and the intestinal microbiome, an interplay that questions whether these gut microbiome changes and the associated immune responses are the cause or the effect of respiratory infections.

Coronavirus-based infections such as SARS and MERS show a range of gastrointestinal tract-like symptoms. As a consequence of the infection, viral specific antibodies and inflammatory cytokines which are produced (Neurath, 2020 , Sundararaman et al., 2020 (Figure 4) , are detectable in the stool samples of COVID-19 patients (Britton et al., 2020) . Interestingly, and even when GIT manifestations are absent or after respiratory recovery from the infection, the virus is thought to remain active in the GIT plausibly in a dormant stage . Gou et al. (Gou et al., 2020) were among the first to report J o u r n a l P r e -p r o o f gut microbiome dysbiosis and immune-inflammatory phenotypes that may predispose patients to severe/fatal consequences of COVID-19. They developed a proteomic based risk score through machine learning and found that the gut microbiome has better predictive capacity when compared to various demographic and laboratory findings including gender, age, BMI, blood pressure and lipid profiles (Gou et al., 2020) . Their study revealed that inflammatory cytokines were positively correlated with Blautia, lactobacilli, and Ruminococci, while Bacteroides, Streptococcus, and Clostridiales were, on the contrary, negatively correlated. Another study found that hospitalized COVID-19 patients had significant alterations in fecal microbiome and mycobiome compared with controls , and correlated disease severity with fecal shedding of the virus.

The microbiome of COVID-19 patients was also enriched with opportunistic fungal (Candida albicans, C. auris, and A. flavus) and bacterial pathogens (Clostridium hathewayi, C. ramosum, and Coprobacillus) . Furthermore, beneficial commensals, such as Faecalibacterium prausnitzii, Bacteroides massiliensis, B.

dorei, B. thetaiotaomicron, and B. ovatus were also depleted in severe COVID-19 patients.

Interestingly enough, these bacteria are known for their anti-inflammatory effects and have been linked to the downregulation of angiotensin-converting enzyme-2 (ACE2) receptors (Geva-Zatorsky et al., 2017 , Miquel et al., 2013 .

In another study, Gu et al. (Gu et al., 2020) examined the gut microbiome data of COVID-19 patients in a plot receiver-operating characteristic (ROC) curves context and determined whether microbiome-based biomarkers can be used to predict the course of COVID-19. As anticipated, they identified five microbial species Actinomyces, Fusicatenibacter, Erysipelatoclostridium, Intestinibacter, and Romboutsia as possible markers to distinguish COVID-19 patients from control groups presenting a GIT microbiome trademark between healthy individuals and COVID-19 patients. The outcome of such studies J o u r n a l P r e -p r o o f displays the importance of the microbiome in identifying non-invasive biomarkers and unravelling potential therapeutic targets for COVID-19 management and treatment. In contrast to these studies however, Britton et al. (Britton et al., 2020) did not find any microbiome composition changes related to COVID-19 severity or gut inflammatory markers, suggesting that only patients treated with antibiotics exhibit substantial microbiome changes with low diversity in microbiome composition.

Accumulating evidence currently support the rationale that the mortality rate of COVID-19 can be greatly reduced with a better understanding of the behavior of the immune system within the course of SARS-COV2 infection. COVID-19 presents with a vast array of clinical outcomes ranging from asymptomatic to severe ARDS including fever hyper-inflammation, coagulopathy and multi-organ failure (Gibson et al., 2020) .

Initially, the virus uses its spike protein, primed by TMPRSS2, to attach to the ACE2 receptor on target cells. The co-expression of ACE2 and TMPRSS2 is essential for initiation of virus infection in the respiratory tract and gastrointestinal epithelial cells including, nasal goblet, alveolar epithelial type II cells, esophageal keratinocytes, colonocytes, pancreatic βcells, cholangiocytes, renal podocytes and proximal tubule cells (Qi et al., 2020) . The initial infection of nasal mucosa triggers a limited innate immune response to the virus that starts propagating towards LRT. There, the virus faces more robust innate immune response characterized by pulmonary infiltration with eosinophils and production of cytokines, interferons, and chemokines (Fung and Liu, 2019) . The PRRs such as TLR family, retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), and NLRs, recognize the expression of PAMPs on infected epithelial and immune cells, such as alveolar macrophages (Fung and Liu, 2019) . Molecular interactions between PRRs and PAMPs induce phagocytosis and trigger intracellular signaling pathways to promote the production of pro-inflammatory can also infect alveolar macrophages and cause a "cytokine storm", which could damage pulmonary tissues and result in multiple organs failure (Wang Chaofu et al., 2020) . In the following section, we summarize the broad innate and adaptive immune responses against SARS-CoV-2.

Recent research related to SARS-CoV-2 have shed light on different aspects of SARS-CoV-2 pathogenesis including viral entry, shedding, clearance or persistence, reinfection, as well as the host immune responses. One of the first identified molecular executor of innate resistance a host mounts in response to viral infection is the release of interferons (IFNs).

These IFNs are potent cytokines that perform multiple roles for blocking viral replication through innate immune cells and priming of adaptive immune responses (Schoggins, 2019) .

Recent transcriptomic studies of SARS-CoV-2-infected bronchial epithelial cells have shown that type I and type III interferon responses were impaired. However, the levels of different chemokines and IL-6 were increased (Blanco-Melo et al., 2020) . Similarly, another study found impairment of IFN-I responses in the peripheral blood of severe COVID-19 patients, which was accompanied by high levels of tumor necrosis factor (TNF) and IL-6, with a reported increase in NF-κB-mediated inflammatory responses . PAMPs can also induce the activation of Toll-like receptors (TLRs) which has been proposed as a player in fatal cases of severe COVID-19, including the development of ARDS and respiratory failure. These cytokines are typically secreted following LPS induced TLR-4 activation, which is a well known endotoxin of gram negative pulmonary bacteria (e.g.

Prevotella, Veillonella, Neisseria, Fusobacteria, etc) . Furthermore, several other studies have highlighted the important role of type I interferons in the development of severe COVID-19. For example, delayed IFN-I responses lead to accumulation of inflammatory monocyte-macrophages, as well as increased levels of pro-inflammatory cytokines and chemokines, along with impairment of virus-specific T cell responses. Indeed, genetic ablation of IFN-αβ receptor and depletion of inflammatory monocyte-macrophages protected mice from lethal infections, with no effect on viral load (Channappanavar et al., 2016 , Lee et al., 2020 . PAMPs are another activator of innate immune cells that can induce anti-viral responses. Studies have revealed that the membrane (M) protein of SARS-CoV can activate IFN-β and NF-κB signaling through a non-canonical TLR-related signaling pathway independent of TRAF3 (Wang and Liu, 2016) . cases (Kuri-Cervantes et al., 2020 , Wilk et al., 2020 . Another study has shown that increased neutrophil-to-lymphocyte ratio can be considered as a prognostic marker of COVID-19 respiratory failure and disease severity. Laing et al. (Laing et al., 2020) observed that patients with severe COVID-19 had depleted pDCs, monocytes, and basophils, while having increased counts of neutrophils. This increased neutrophil count can be attributed to superadded bacterial infections in COVID-19 infected patients. However, interleukin (IL)-8, IL-6, IL-10, and interferon gamma-induced protein 10 (IP-10) concentrations were higher in COVID-19 patients and were concomitant with disease severity. Furthermore, IP-10 levels were associated with IFN-γ, while IFN-α/β responses were reported low in COVID-19 patients (Laing et al., 2020 , Lee et al., 2020 . Similarly, Wilk et al. (2020) reported a drop in DC, pDC, NK, and γδ T cells in ARDS-associated COVID-19 patients. Alveolar macrophages were significantly reduced while monocytes-derived inflammatory macrophages (FCN1 + and SPP1 + ) dominated in patients with severe COVID-19. These inflammatory macrophages upregulated INF signaling genes, monocytes recruiting chemokines, and pro-fibrotic cytokine (Wilk et al., 2020) . However, the available literature does not always coincide and report heterogeneous phenotypic patterns of neutrophils, CD14+ and CD16+ monocytes, as well as cytokines and IFN secretions across several J o u r n a l P r e -p r o o f 22 COVID-19 studies (Kuri-Cervantes et al., 2020 , Laing et al., 2020 , Lee et al., 2020 , Merad and Martin, 2020 , Wilk et al., 2020 . Therefore, the presented COVID-19 innate immune traits decipher multiple immunopathology and immune protection settings, emphasizing reinvestigation of immune cells and their secreted molecules in other COVID-19 cohorts, which are strongly associated with disease severity and clinical outcome.

To investigate the adaptive immune response in COVID-19 patients, several studies performed in-depth immune-phenotyping to identify relationships between cell-mediated responses, disease severity and poor clinical outcomes in COVID-19 cases (Mathew et al., 2020) . Indeed, CD4+ and CD8+ T cells have been characterized as a key player in SARS-CoV-2 clearance and found to be well correlated with IgG and IgA antibody titers in COVID-19 patients. Interestingly, SARS-CoV-2-reactive CD4+ T cells were detected in unexposed individuals, indicating a cross-reactivity between circulating coronaviruses and SARS-CoV-2 (Grifoni et al., 2020 , Pia, 2020 , Weiskopf et al., 2020 . reported lower levels of CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells in COVID-19 patients, especially in severe cases. In particular, CD8+ T cells and CD4+/CD8+ ratio showed a significant association with inflammatory status in COVID-19 patients (Wang F. et al., 2020) . Moreover, another potential studied immunological marker was the levels of IFN-γ released by CD4+ T cells, which was found lower in severe cases in comparison to moderate cases . Microbial dysbiosis due to loss of commensals along with decreased SCFs negatively impact Treg populations that are crucial for suppressing an overactive immune response. Data available from SARS-CoV-2 serological studies indicate that IgM and IgG antibodies to SARS-CoV-2 are detected between 6 to 15 days post-COVID-IgM and 79.8% for IgG starting from day-15 following COVID-19 onset . Serological studies that measure levels of antibodies in patients and recovered individuals over an extended period of time demonstrate a decline in the antibody concentration after 8 months and therefore question protective long term immunity against SARS-CoV-2, however further studies are needed in this direction (Anichini et al., 2021 , Zhou et al., 2021 . Furthermore, preliminary data by the COVID-IP project identified several prominent immunological signatures in peripheral blood of COVID-19 that are linked to disease progression, including CXCL10/IP10 over-expression, T cell proliferation, and basophil and plasmacytoid dendritic cell depletion (Laing et al., 2020) .

Although, there is a general consensus that an over-activated immune system leads to massive pulmonary damage in COVID-19 patients, the reasons underpinning variable disease spectrum observed in these patients have yet to be delineated. Conventional research direction is focused on the role of genetic susceptibility, viral strain, and comorbidities in determining COVID-19 outcome. In this review, we focused on the rather overlooked role of microbiome dysbiosis in two major organs namely, GIT and respiratory tract, that have been involved in COVID-19 disease severity. In this context, some of the factors that are identified are microbiota diversity affected by ageing and comorbidities as well as antibiotic usage. There is compelling evidence that the milieu of gut flora influences pulmonary immune responses. Studies indicate a unique crosstalk that exists between the pulmonary and gut microbial compartments, which influences microbial profiles in both. Interestingly, these microbial compartments are important for educating the innate and adaptive immune cells present at these mucosal interfaces. The gut microbiota has been shown to modulate several innate and adaptive immune-regulatory pathways (e.g., SCFAs released in the gut exhibit a protective role by limiting immune system over-activation). These observations might 

The authors declare no conflict of interest.

J o u r n a l P r e -p r o o f 

Commensal bacteria calibrate the activation threshold of innate antiviral immunity

Microbiota and the control of blood-tissue barriers

Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel medicine and infectious disease 2020

Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19

Human Microbiome and its Association With Health and Diseases

Microbiota and Gut-Lung Connection

Antibody response to SARS-CoV-2 in infected patients with different clinical outcome

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City

Viral and bacterial interactions in the upper respiratory tract

Microbial burden and viral exacerbations in a longitudinal multicenter

SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19

Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Clinical and immunological features of severe and moderate coronavirus disease 2019

The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem

Altered Gut Microbiota in Infants is Associated with Respiratory Syncytial Virus Disease Severity

Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients

Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients

Influenza virus affects intestinal microbiota and secondary salmonella infection in the gut through type I interferons

Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography

Lung microbiota predict clinical outcomes in critically ill patients

Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome

An interactive web-based dashboard to track COVID-19 in real time

Respiratory microbes present in the nasopharynx of children hospitalised with suspected pulmonary tuberculosis in Cape Town

The nasopharyngeal microbiota in patients with viral respiratory tract infections is enriched in bacterial pathogens

Gut microbiota: the conductor in the orchestra of immune-neuroendocrine communication

Human infection caused by Clostridium hathewayi

Acute Infection Disrupts the Respiratory Microbiome of Lung Transplant Recipients

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

The lung tissue microbiota features of 20 deceased patients with COVID-19

Human coronavirus: host-pathogen interaction

Differences in the distribution of bifidobacterial and enterobacterial species in human faecal microflora of three different (children, adults, elderly) age groups

Mining the human gut microbiota for immunomodulatory organisms

COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS

Gut microbiota may underlie the predisposition of healthy individuals to COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Respiratory disease following viral lung infection alters the murine gut microbiota

Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza

Clinical characteristics of coronavirus disease 2019 in China

Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT

Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia

The respiratory tract microbiome and its relationship to lung cancer and environmental exposures found in rural China

Microbiota regulates immune defense against respiratory tract influenza A virus infection

COVID 19 mortality: Probable role of microbiome to explain disparity

The microbiome of the upper respiratory tract in health and disease

Comprehensive mapping of immune perturbations associated with severe COVID-19

A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis

Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

of potential respiratory pathogens by pH1N1 viral infection

Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

Lung homeostasis: influence of age, microbes, and the immune system

The gut-lung axis in respiratory disease

Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients

Feasibility of using alternative swabs and storage solutions for paired SARS-CoV-2 detection and microbiome analysis in the hospital environment

Faecalibacterium prausnitzii and human intestinal health

The lung microbiome in health and disease

Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease

Induction of type I interferons by bacteria

Gut microbiome and aging: Physiological and mechanistic insights

Mucosal immunity and the microbiome

COVID-19 and immunomodulation in IBD

The lung microbiome, immunity, and the pathogenesis of chronic lung disease

Agerelated changes in gut microbiota composition from newborn to centenarian: a crosssectional study

Control of antiviral immunity by pattern recognition and the microbiome

Targeting human TLRs to combat COVID-19: A solution

SARS-CoV-2-reactive T cells in patients and healthy donors

The Human Microbiome Project in 2011 and beyond

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Determinants of COVID-19 disease severity in patients with cancer

99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Darwinian medicine and the 'hygiene'or 'old friends' hypothesis

Quantitative detection of Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in patients with new influenza A (H1N1)/2009 and influenza A/2010 virus infection

Physiology of obesity and effects on lung function

Interferon-Stimulated Genes: What Do They All Do?

Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production

Molecular paths linking metabolic diseases, gut microbiota dysbiosis and enterobacteria infections

Genomic Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in Patients With Coronavirus Disease

Immune response and mortality risk relate to distinct lung microbiomes in patients with HIV and pneumonia

The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis

Role of the gastrointestinal tract microbiome in the pathophysiology of diabetes mellitus

Molecular analysis of the caecal and tracheal microbiome of heat-stressed broilers supplemented with prebiotic and probiotic

Impact of physical exercise on gut microbiome, inflammation, and the pathobiology of metabolic disorders

Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age

Role of probiotics to combat viral infections with emphasis on COVID-19

Covid-19: Perspectives on Innate Immune Evasion

Dietary fiber confers protection against flu by shaping Ly6c− patrolling monocyte hematopoiesis and CD8+ T cell metabolism

Effect of advanced HIV infection on the respiratory microbiome

Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients

Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia

Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 celldependent inflammation

The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Functions as a Novel Cytosolic Pathogen-Associated Molecular Pattern To Promote Beta Interferon Induction via a Toll-Like-Receptor-Related TRAF3-Independent Mechanism

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

A single-cell atlas of the peripheral immune response to severe COVID-19

A poke into the diversity and associations within human anterior nare microbial communities

Profiling bacterial community in upper respiratory tracts

Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis

Altered Airway Microbiota Composition in Patients With Pulmonary Hypertension

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals

Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19

Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge

Alterations in Gut Microbiota of patients with COVID-19 during time of hospitalization

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization